CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) like anti‐PD‐1 (nivolumab and pembrolizumab), anti‐PD‐L1 (atezolizumab, avelumab and durvalumab) and anti‐CTLA‐4 (ipilimumab and tremelimumab) antibodies have come a long way in improving a patient's progression‐free (PFS) and/or overall survival (OS) during advanced stages of NSCLC.